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SUMMARY

During tumor progression, lysosome function is often maladaptively upregulated to match the high energy
demand required for cancer cell hyper-proliferation and invasion. Here, we report that mucolipin TRP channel
1 (TRPML1), a lysosomal Ca2+ and Zn2+ release channel that regulates multiple aspects of lysosome function,
is dramatically upregulated in metastatic melanoma cells compared with normal cells. TRPML-specific synthetic agonists (ML-SAs) are sufficient to induce rapid (within hours) lysosomal Zn2+-dependent necrotic cell
death in metastatic melanoma cells while completely sparing normal cells. ML-SA-caused mitochondria
swelling and dysfunction lead to cellular ATP depletion. While pharmacological inhibition or genetic silencing
of TRPML1 in metastatic melanoma cells prevents such cell death, overexpression of TRPML1 in normal cells
confers ML-SA vulnerability. In the melanoma mouse models, ML-SAs exhibit potent in vivo efficacy of suppressing tumor progression. Hence, targeting maladaptively upregulated lysosome machinery can selectively eradicate metastatic tumor cells in vitro and in vivo.
INTRODUCTION
Once metastasized, melanoma skin cancer responds poorly to
the traditional anti-cancer options, calling for a need to develop
novel treatment strategies (Narayana et al., 2013; Welsh et al.,
2016). Lysosomes, the cellular hub in metabolism, protein degradation, and nutrient sensing, play an indispensable role in cell
survival and growth in normal physiology (Lawrence and Zoncu,
2019). In the metastatic cancer, lysosomes are often ‘‘transformed’’ to be hypertrophic (Katheder et al., 2017; Kroemer
and Jäättelä, 2005), actively contributing to tumor progression,
not only in cancer cell proliferation and survival by providing nutrients via macromolecule degradation but also in cancer invasion and metastasis by secreting lysosomal hydrolases to digest
the extracellular matrix (Finicle et al., 2018; Hämälistö and Jäättelä, 2016). Due to a high energy demand of cancer cells, the
function of lysosomes is often adaptively or maladaptively upregulated to meet the metabolic requirement of cancer cells (Kallunki et al., 2013; Piao and Amaravadi, 2016). Given the heavy
dependence on lysosome machinery for hyper-proliferation
and invasion, cancer cells are particularly sensitive to lysosome
disruptions (Serrano-Puebla and Boya, 2018). Lysosome inhibitors and/or inducers of lysosome membrane permeability are
reportedly effective in triggering cancer cell death (McAfee
et al., 2012; Petersen et al., 2013; Tardy et al., 2006). However,
broad-spectrum lysosome inhibition, such as inhibitors of vacu-

olar type ATPase (v-ATPase), may inevitably compromise the
functions of normal cells and tissues (Pérez-Sayáns et al.,
2009). Hence, it is more desirable to target specific lysosomal
machineries that operate in normal physiology but are maladaptively upregulated in cancer.
Mucolipin TRP channel 1 (TRPML1/MCOLN1; ML1) is a Ca2+
and Zn2+/Fe2+ dually permeable cation channel predominantly
localized on the membranes of late endosomes and lysosomes
(LELs) in all mammalian cell types (Cheng et al., 2010; Dong
et al., 2008). The related ML2 and ML3 channels are also permeable to Ca2+, as well as heavy metal ions, but are more restrictively expressed (Cheng et al., 2010; Li et al., 2019). Using
TRPML-specific synthetic agonists (ML-SAs) and synthetic
inhibitors (ML-SIs), which bind directly to TRPML proteins in
the atomic-resolution co-structures (Schmiege et al., 2017;
Schmiege et al., 2021), we and others have demonstrated that
TRPML channels, especially ML1, play essential roles in various
lysosomal functions, which include lysosome movement, membrane trafficking, lysosomal exocytosis, lysosome biogenesis,
and heavy metal homeostasis (Dong et al., 2008; Li et al.,
2016; Minckley et al., 2019; Peng et al., 2020; Samie et al.,
2013; Yu et al., 2020).
While a high level of ML1 expression may serve as a favorable
prognostic marker for several types of cancer, RNA sequencing
(RNA-seq) analysis revealed that the highest expression among
them is in melanoma (WebLink, 2019). Although several recent
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Figure 1. Lysosomal ML1 is upregulated in metastatic melanoma cells
(A) Representative images of human tissue sections from normal skin, nevus (benign tumor), and metastatic melanoma immunostained with an anti-ML1 antibody
(brown DAB staining). Scale bar, 200 mm.
(B) Quantification of ML1 immunostaining from normal skin tissue (Normal; n = 2 cases), nevus (Benign; n = 8 cases), and metastatic melanoma (Mets; n = 8
cases). Each open circle represents one case.
(C–E) Whole-endolysosome ML1 currents (IML1) were activated by ML-SA1 (20 mM), a synthetic agonist of ML1, in an immortalized human melanocyte (C), a
MeWo cell (D), and a M12 cell (E). Currents were recorded with a ramp voltage protocol from 120 to +120 mV (only partial voltage ranges are shown). Pipette
(luminal) solution was a standard external (Tyrode’s) solution adjusted to pH 4.6 to mimic the acidic environment of the lysosome lumen. Bath (cytoplasmic)
solution was a K+-based solution (140 mM K-gluconate). Note that the inward currents indicate cations flowing out of endolysosomes.
(F) Mean current densities of whole-endolysosome IML1 in normal melanocytes (n = 4), MeWo cells (n = 7), and M12 cells (n = 12). Each open circle represents one
endolysosome/patch/cell; average data are presented as mean ± SEM; **p < 0.01.

loss-of-function studies suggest that ML1 inhibition or knock
down could reduce cancer cell proliferation, the effects were
marginal even over time courses of days (Jung et al., 2019; Shekoufeh Almasi et al., 2020; Xu et al., 2019). Whereas no gross
growth phenotype is seen in Trpml1 knockout (KO) mice and
type IV mucolipindosis patients (Venugopal et al., 2007),
the Genome-wide Cancer Dependence Map showed that ML1
is dispensable for cancer cell survival (DepMap, https://
depmaporg/portal/gene/MCOLN1?tab=overview). Consistent
with these observations, we found that prolonged inhibition of
ML1 using ML-SIs that are much more potent than the published
ones barely inhibited the growth of multiple cancer cell lines (unpublished data). In the current study, we found that small-molecule activation, but not inhibition of ML1, induced selective cell
death of metastatic melanoma in vitro and in vivo.
RESULTS
Lysosomal ML1 channels are upregulated in metastatic
melanoma cells
We examined the protein expression levels of ML1 in normal skin
tissues, nevus (benign), and metastatic melanoma using immunohistochemistry with a ML1-specific antibody (Sahoo et al.,
2017). Much stronger immunoreactivities were seen in the metastatic melanoma tissues compared with normal skin and benign
nevus (Figures 1A and 1B). Consistently, in two highly metastatic
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melanoma cell lines, MeWo and M12, which have been intensively studied for their high metastatic capabilities in vitro and
in vivo (Du et al., 2017; Pietrobono et al., 2020; Shiku et al.,
1976; Xie et al., 1997), quantitative real-time PCR and western
blotting analyses revealed 2-to-4-fold increases in the mRNA
and protein expression levels of ML1 compared with normal,
non-cancerous immortalized human melanocytes (Figures
S1A–S1C).
To compare the channel activities of lysosomal ML1 in the
cells, we performed patch-clamp recordings on chemically
enlarged LELs (Dong et al., 2008) isolated from normal melanocytes, MeWo, and M12 cells. Whole-endolysosome ML1-mediated currents (IML1) were activated by ML-SAs (Figures 1C–1E),
which included ML-SA1 (Shen et al., 2012) and the more potent
ML-SA5 and ML-SA8 (Sahoo et al., 2017; Yu et al., 2020) (potency SA1 < SA5 < SA8; Figure S1E), and inhibited by ML-SI3
and ML-SI4 (Sahoo et al., 2017; Yu et al., 2020) (Figure S1F).
Note that the specificities of ML-SAs and ML-SIs have been previously validated using ML1 KOs (Sahoo et al., 2017; Shen et al.,
2012; Yu et al., 2020; Zhang et al., 2016) and confirmed in
the atomic-resolution co-structures (Schmiege et al., 2017;
Schmiege et al., 2021). Remarkably, whole-endolysosome IML1
was 30-to-75-fold larger in MeWo and M12 cells compared
with normal melanocytes (Figure 1F). It is possible that in the
metastatic melanoma cells, additional posttranslational mechanisms, e.g., increased lysosomal delivery of ML1 and accessory
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Figure 2. Selective cytotoxic effects of ML-SAs on metastatic melanoma cells
(A–C) Dose-dependent effects of SA5 and SA8 on cell viabilities of normal melanocytes, MeWo, and M12 cells, which were measured using the CellTiter-Glo ATP
assay 24 h after drug treatment. The average data represent mean ± SEM from three independent experiments, each with triplicates.
(D) PI staining of MeWo and M12 cells in the presence or absence of SA5 (3 mM). Normal melanocytes and MeWo cells were drug treated for 6 h, and M12 cells
were drug treated for 3 h. Overlay phase contrast (Ph) images are also shown. Scale bar, 25 mm.
(E) The percentage of PI-positive cells in the presence of SA5 (3 mM, the left panels), as in (D), and SA8 (1 mM, right panels). Each open circle represents the
average data from one batch of cells for each independent experiment.
(F and G) Dose-dependent effects of SA5/8 on the percentages of PI-positive MeWo (6 h) and M12 (3 h) cells.
(H) The effects of ML-SAs (3 mM SA5 or 1 mM SA8 for 12 h) on the cell viabilities of multiple cell types (n = 3 independent experiments).
(I) Overlay phase contrast and fluorescence images of PI-stained SA5 (3 mM)-treated MeWo (for 6 h) and M12 (for 3 h) cells in the presence or absence of ML-SIs
(SI3 and SI4, 20 mM). Scale bar, 25 mm.

(legend continued on next page)

Cell Reports 37, 109848, October 19, 2021 3

ll
OPEN ACCESS

factors, may contribute to the much more dramatic upregulation
in the lysosomal currents, relative to the mild increases in the total mRNA and protein expression levels.
Considering the established role of ML1 in activating transcription factor EB (TFEB), a master regulator of lysosome biogenesis
(Li et al., 2019; Medina et al., 2015; Napolitano and Ballabio,
2016), we studied whether other lysosomal machineries were
also upregulated in the metastatic melanoma cells. The protein
expression level of lysosome-associated membrane protein 1
(LAMP1), a commonly used lysosomal marker (Saftig and Klumperman, 2009), was also increased by more than 2 folds in both
MeWo and M12 cells compared with normal melanocytes (Figures S1B and S1D). In addition, the fluorescent intensity of LysoTracker, a marker for lysosomal acidification (Tasdemir et al.,
2008), was also increased (Figure S1G). It is worth noting that
LAMP1 expression is reportedly elevated in aggressive brain tumors (Jensen et al., 2013). Taken together, these results suggest
that lysosomal ML1 channels, or likely lysosome biogenesis in
general, were upregulated in metastatic melanoma cells.
Selective cytotoxicity of ML-SAs to metastatic
melanoma cells
We next investigated the roles of ML1 upregulation in the growth
and survival of metastatic melanoma cells. No significant effects
of ML-SI3 or ML-SI4 (0.1–100 mM for 12 h) on M12 or MeWo cell
viability, measured by the cellular ATP level with the CellTiter-Glo
ATP assay, were observed (Figure S2A). In contrast, both MLSA5 and ML-SA8 induced substantial cell death in M12 and
MeWo cells while completely sparing normal melanocytes (Figures 2A–2C and S2B). Within 0.5 to 2 h, ML-SA-treated MeWo
and M12 cells exhibited cell round-up and swelling, which are
morphological changes characteristic of necrotic cell death
(Kroemer et al., 2009) (Figure S2B; Videos S1 and S2), followed
by reduced cell viability (Figures 2B, 2C, and 2H) and loss of
membrane integrity as detected by propidium iodide (PI) staining
(Figures 2D, 2E, and S2B). ML-SA-induced cell death occurred in
a dose- (Figures 2B, 2C, 2F, and 2G) and time-dependent
manner (Figure S2B). In the PI staining assay used for the further
cytotoxicity analyses, we set the treatment dose to 3 mM and
1 mM for ML-SA5 and ML-SA8, respectively, and the treatment
time to 3 h and 6 h for M12 and MeWo cells, respectively.
Notably, the cytotoxic effects of ML-SAs were completely
blocked by a co-treatment of ML-SI3 or ML-SI4 (Figures 2I–2K
and S2C), indicating the on-target specificity of ML-SA5/8 in
the cell-death assays. ML-SA1, which was much less potent
than ML-SA5 or ML-SA8 in the channel assays (Figures S1E
and S1F), had only weak cytotoxic effects in the high concentrations (>50 mM) (data not shown), so ML-SA1 was not studied
further in the cell-death assays. In a sharp contrast, noncancerous human melanocytes displayed no obvious vulnerability to ML-SA treatment (Figures 2A, 2D, 2E, 2H, and S2B). In
addition, ML-SA-induced cytotoxicity was not observed in
HEK293 cells, human fibroblasts, or two commonly used cancer

Article
cell lines: HeLa and SH-SY5Y (Figures 2H and S2D). On the other
hand, significant but slightly weaker cytotoxicity was seen in
MDA231-BrM2, a human breast-to-brain metastatic cancer
cell line (Bos et al., 2009) (Figure 2H). Put together, these results
suggest that ML-SAs selectively induce rapid, necrosis-like cell
death in metastatic melanoma cells and possibly in other metastatic cancer cells as well.
ML-SA-induced cytotoxicity is dependent on the
expression level of ML1
We next studied whether ML1 is required for ML-SA-induced cell
death of metastatic melanoma cells by silencing the expression
of ML1 using RNA interference (Kukic et al., 2013). In the siML1transfected, ML1 knocking-down MeWo and M12 cells, in which
whole-endolysosome IML1 was reduced by more than 80% (Figure 3A), ML-SA-induced cell death was significantly decreased
(Figures 3B–3D), indicating that ML1 is required for ML-SA cytotoxicity in the metastatic melanoma cells. Note that knock down
efficiency and genetic compensation (e.g., ML2/3 channels)
might have contributed to the residual ML-SA cytotoxicity in
the siML1-transfected cells.
We also investigated whether increasing the expression of
ML1 in ML-SA-insensitive cells is sufficient to confer ML-SA
vulnerability. Since HEK293 is not sensitive to ML-SA treatment
(Figure S2D), we performed the test in the ML1-ovexpressing
HEK293 cells. In the Tet-On-HEK293-GCaMP7-ML1 stable cells
(Zhang et al., 2019), in which ML1 expression was induced by
doxycycline (Dox), cells became vulnerable to ML-SAs upon
Dox application (Figure 3E). Likewise, HEK293 cells that were
transiently transfected with EGFP-ML1 (HEK ML1 OE) also
became sensitive to ML-SA treatment, and the vulnerability
was diminished by ML-SIs (Figures 3F, 3G, S2E, and S2F).
Hence, ML1 upregulation may have played an essential role in
ML-SA cytotoxicity in metastatic melanoma cells.
ML-SA-induced cell death is a Zn2+-dependent process
Lysosomal ML1 is a non-selective cation channel that is permeable to Ca2+, as well as heavy metal ions such as Fe2+ and Zn2+
(Dong et al., 2008). Give the well-established role of Ca2+ in cell
death (Orrenius and Nicotera, 1994), we first examined whether
Ca2+ is required for ML-SAs’ cytotoxicity in M12 and MeWo cells.
Surprisingly, BAPTA-AM, a membrane-permeable Ca2+ chelator
(Garrity et al., 2016) that readily blocked ML-SA-evoked lysosomal Ca2+ release and TFEB nuclear translocation (Figures
S3A and S3B), failed to prevent ML-SA’s cytotoxicity in metastatic melanoma cells (Figures 4A–4D). Likewise, EGTA-AM,
another Ca2+ chelator, was also without effect (Figure S3C).
Furthermore, cyclosporin A (CsA), a calcineurin inhibitor that
reportedly blocks ML-SA-induced Ca2+-dependent TFEB nuclear translocation (Medina et al., 2015), or knocking down
TFEB expression also failed to prevent ML-SA-induced cell
death (Figures S3D and S3E). Hence, the well-documented
ML1-Ca2+-TFEB pathway (Li et al., 2019; Napolitano and

(J) The percentage of PI-positive cells under indicated conditions. Each open circle represents one batch of cells. Note that the control (Ctrl) groups of MeWo and
M12 treated with SA5 or SA8 are re-plotted from (E), as they were from the same experiments.
(K) Cell viability analysis of MeWo and M12 cells treated with SA5 in the presence or absence of ML-SI3 (12 h). In all panels, average data are presented as
mean ± SEM; ***p < 0.001.
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Figure 3. ML1 is required for ML-SA-induced cell death
(A) Mean current densities of whole-endolysosome IML1 in Ctrl or ML1-specific siRNA (siML1)-transfected MeWo and M12 cells. Each open circle represents one
endolysosome/cell/patch.
(B) PI-staining of Ctrl or siML1-transfected MeWo and M12 cells in the presence of SA5 (3 mM) for 3 to 6 h. The overlay phase contrast and PI images are also
shown. Scale bar, 25 mm.
(C and D) The percentages of PI-positive control or siML1-transfected cells treated with SA5 (C) or SA8 (D).
(E) Dose-dependent effects of SA5 (left panel) and SA8 (right panel) (12 h) on cell viability of Tet-On HEK293-GCaMP7-ML1 cells with (Dox+) or without doxycycline (Dox–) induction.
(F) PI staining of HEK293 and HEK293 transiently expressing EGFP-ML1 (HEK ML1 OE) cells under indicated drug treatments for 6 h. The overlay phase contrast
images are shown together with the green (EGFP-ML1) and red (PI staining) fluorescence channels. White arrows point to the EGFP-positive cells (i.e., with
successful expression of EGFP-ML1) that are also PI positive. Scale bar, 25 mm.
(G) The percentages of PI-positive ML1-overexpressing HEK293 cells (HEK293 ML1 OE) upon SA5 treatment (3 mM) in the presence and absence of ML-SI3/4
(20 mM), as shown in (F). Average data are presented as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001.

Ballabio, 2016) might not play a dominant role in ML-SA-induced
cell death.
In contrast, N,N,N,N-Tetrakis(2-pyridylmethyl)-ethylenediamine (TPEN), a membrane-permeable, relatively specific, high-

affinity Zn2+ chelator (Radford and Lippard, 2013) (Figure S4A),
which exhibited no inhibitory effect on lysosomal Ca2+ release
or TFEB nuclear translocation (Figures S3A and S3B), completely
prevented ML-SA-induced cytotoxicity in M12 and MeWo cells
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Figure 4. Lysosomal Zn2+ release is required for ML-SA-induced cell death
(A) The effects of SA5 (3 mM) treatment on PI staining of MeWo (for 6 h) and M12 (for 3 h) cells that were pretreated with BAPTA-AM (10 mM) or TPEN (2.5 mM).
(B) The percentages of PI-positive cells as shown in (A). Each open circle represents one batch of cells. Note that the control groups of MeWo and M12 cells
treated with ML-SA5 are re-plotted from Figure 2E, as they were from the same experiments.
(C and D) Cell viability analysis of MeWo (C) and M12 (D) cells treated with indicated chemicals for 12 h.
(E) PI staining of HEK293 and HEK293 transient expressing of EGFP-ML1 (HEK ML1 OE) cells under indicated drug treatments for 6 h. Phase contrast overlay
images are shown together with the green (EGFP-ML1) and red (PI staining) fluorescence channels. White arrows point to the EGFP-positive cells that are also PI
positive. Scale bar, 25 mm.

(legend continued on next page)
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(Figures 4A–4D, S4B, and S4C). Likewise, 1,10-phenanthroline
(1,10-PT), another zinc chelator (Yang et al., 2007) (Figure S4A),
also significantly reduced ML-SA-induced melanoma cell death
(Figure S4D). In the ML1-overexpressing HEK293 cells, TPEN,
but not BAPTA-AM, diminished ML-SA’s cytotoxicity (Figuress
4E, 4G, S4E, and S4F). Considering that ML1 is a Zn2+-permeable
channel (Figure S4G), the collective results suggest that ML1’s
Zn2+ permeability, but not its Ca2+ permeability, underlies
ML-SA’s cytotoxicity.
Activation of ML1 releases lysosomal Zn2+ to cause cell
death in metastatic melanoma cells
Lysosomes are vesicular Zn2+ stores and a major source for the
free Zn2+ pool in the cytoplasm (Haase and Beyersmann, 1999;
Palmiter et al., 1996). A link between ML1 and lysosomal Zn2+
release has been recently established (Cuajungco et al., 2014;
Minckley et al., 2019); in ML1-deficient cells, cellular Zn2+ is
reportedly accumulated in the lysosomes (Eichelsdoerfer et al.,
2010; Kukic et al., 2013). We hypothesize that ML-SA’s cytotoxicity is attributed to lysosomal Zn2+ release upon ML1 activation.
FluoZin-3-AM, a cell membrane-permeable Zn2+-sensitive
fluorescent dye (Kd = 15 nM), can be used to monitor not only cytoplasmic [Zn2+] but also vesicular [Zn2+], due to its relative insensitivity to acidic pH (Devinney et al., 2005) (Figure S4H). In MeWo
and M12 cells, the strongest FluoZin-3 signal was detected in
the vesicular compartments that were LysoTracker-positive (Figure 4H), suggesting that lysosomes are the major intracellular Zn2+
stores in MeWo and M12 cells. Notably, ML-SA5 significantly
decreased vesicular FluoZin-3 fluorescence in M12 cells (Figures
4I and 4J). In the HEK293 and MeWo cells that were transfected
with ML1 tagged with GZnP3 (genetically encoded Zn2+ indicator,
GZnP3-ML1), but not in the cells that were transfected with
GZnP3-Rab7 (Minckley et al., 2019), ML-SA induced increases
in the cytoplasmic GZnP3 signal (Figures 4K and 4L). Taken
together, these data suggest that ML-SAs activate lysosomal
ML1 to induce Zn2+ release from lysosomal Zn2+ stores.
In the MeWo and M12 cells that were incubated with extracellular Zn2+, vesicular Zn2+ levels were found to be elevated
(Figure 4M). In these cells, ML-SA5-induced cytotoxicity was
synergistically increased (Figure 4N), suggesting that ML1 activation causes cell death via Zn2+ release from lysosomes in metastatic melanoma cells
ML-SAs induced mitochondrial swelling and dysfunction
To explore the cell death mechanism(s) underlying ML-SA’s cytotoxicity, we tested a panel of established inhibitors for various cell
death pathways, which included necrostatin-1 (Nec-1) for nec-
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roptosis (Degterev et al., 2005), pan-caspase inhibitor z-VADfmk for apoptosis (Cain et al., 1996), iron chelator deferoxamine
(DFO) for ferroptosis (Dixon et al., 2012), and bafilomycin A1
(Baf-A1) and chloroquine (CQ) for autophagic cell death (Tasdemir
et al., 2008). None of the tested cell-death inhibitors prevented
ML-SA-induced cytotoxicity (Figures S5A–S5E), suggesting that
ML-SAs induce a cell-death mechanism distinct from apoptosis,
necroptosis, ferroptosis, or autophagic cell death.
Cytosolic Zn2+ overload is known to cause mitochondrial damage (Dineley et al., 2003; Sheline et al., 2000), which in turn may
cause a rapid drop in cellular ATP levels, as was observed in
ML-SA-treated MeWo and M12 cells (Figures 2B and 2C). MitoTracker staining (Gao et al., 2001) revealed that in MeWo and
M12 cells, but not in normal melanocytes, mitochondria became
swollen and fragmented within 0.5 to 1 hour post ML-SA treatment (Figures 5A–5C). Such morphological changes of mitochondria were not seen in cells that were co-treated with ML-SIs or
TPEN (Figures 5D and 5E). Extensive mitochondrial swelling
was also evident in the ML-SA-treated cells under the transmission electron microscopy (TEM) examination (Figures 5F and
5G). Tetramethylrhodamine methyl ester (TMRM) staining revealed that ML-SA5 treatment also caused a loss of mitochondrial
membrane potential in M12 cells (Figure S6). Collectively, these
results suggest that ML-SAs caused mitochondrial damage and
cellular ATP depletion via ML1 activation and subsequent lysosomal Zn2+ release.
ML-SAs inhibit tumor progression in advanced
melanoma mouse models
To evaluate the therapeutic efficacy of ML-SAs in vivo, we engineered MeWo and M12 cells stably expressing both the fluorescent protein mCherry and the bioluminescent protein firefly luciferase (Fluc) (Du et al., 2017). The modified MeWo and M12 cells,
referred to as MeWo-FmC and M12-FmC cells, exhibit similar
cell morphology, proliferation, migration, and ML-SA sensitivity
compared to the unmodified parental cells (data not shown). In a
subcutaneous xenograft melanoma mouse model, in vivo bioluminescence imaging was performed weekly to monitor tumor
growth. In MeWo-FmC-bearing mice that were randomly separated into vehicle versus ML-SA5-treated groups, intraperitoneal
(i.p.) injection of ML-SA5 (5 mg/kg three times per week with
drug administration starting one week post-tumor cell inoculation)
resulted in a substantial reduction in tumor growth in vivo (Figures
6A–6C) without causing obvious systemic toxicity (Figure 6D).
Meanwhile, i.p. injection of ML-SA5 (three times per week) into
subcutaneous-tumor-bearing mice significantly prolonged animal
survival post-tumor implantation (Figure S7).

(F) The percentages of PI-positive ML1-overexpressing HEK293 cells (HEK293 ML1 OE) upon SA5 treatment (3 mM) in the presence and absence of BAPTA-AM
(10 mM) or TPEN (2.5 mM), as shown in (E). Note that the left two columns are re-plotted from Figure 3G, as they were from the same experiments.
(G) Cell viability analysis of HEK293-GCaMP7-ML1 cells (with Dox induction) in the presence of SA5, BATPA-AM, and TPEN for 12 h.
(H) Fluorescence images of MeWo and M12 cells stained with both FluoZin-3 (-AM) and LysoTracker. Scale bar, 5 mm.
(I) FluoZin-3 staining of M12 cells treated with DMSO (Ctrl) and SA5 (3 mM) for 30 min. Scale bar, 5 mm.
(J) Statistical analysis of relative FluoZin-3 intensity in control (n = 55 cells) and SA5 treatment (n = 56 cells) experiments, as shown in (I).
(K) The effects of SA1 on GZnP3 imaging of MeWo cells transfected with GZnP3-ML1 or GZnP3-Rab7 in the presence of 100 mM Zn2+.
(L) The rates of SA1-induced Zn2+ flux in GZnP3 (ML1- or Rab7-) transfected HEK293 and MeWo cells (calculated as in K).
(M) FluoZin-3 imaging of M12 cells that were incubated with a normal (Ctrl) or high Zn2+ (100 mM) growth medium for 12 h.
(N) Cell viability analysis of M12 (left panel) and MeWo (right panel) cells that were treated with indicated chemicals for 12 h. All data are mean ± SEM; *p < 0.05,
**p < 0.01, ***p < 0.001.
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Figure 5. ML-SAs cause mitochondrial swelling in metastatic melanoma cells
(A) Live imaging of MitoTracker-loaded normal melanocytes (left panels, 60 min), MeWo (middle panels, 60 min), and M12 (right panels, 30 min) cells under DMSO
(Ctrl) or SA5 (3 mM) treatment. Scale bar, 10 mm.
(B and C) Statistical analysis of mitochondrial swelling in melanocytes, MeWo, and M12 cells that were treated with SA5 (3 mM) or SA8 (1 mM) for 30 or 60 min. Each
open circle represents the average result from one batch of cells.
(D and E) The effects of ML-SIs and TPEN on mitochondrial swelling in SA5 (D) or SA8 (E)-treated MeWo and M12 cells. Note that the control groups of MeWo and
M12 treated with SA5 or SA8 are re-plotted from (B) and (C), as they were from the same experiments.
(F) Representative transmission electron microscopy (TEM) images of M12 cells that were treated with DMSO (Ctrl) or SA5 (3 mM) for 30 min. M, mitochondria.
Scale bar, 200 nm.
(G) Statistical analysis of mitochondrial size in control (n = 14 mitochondria from 3 cells) and SA5-treated cells (n = 22 mitochondria from 5 cells). All data are mean
± SEM; **p < 0.01.

Since M12 cells are primary melanoma cells derived from melanoma brain metastases (MBM) patients, we created a mouse
model of MBM by implanting M12-FmC cells into mouse brain.
In mice bearing MBM, single intracranial administration of MLSA8 (10 mM/5 mL) was sufficient to markedly suppress MBM
cell growth with a survival benefit (Figures 6E–6G). Collectively,
our results have demonstrated that pharmacological activation
of ML1 using small-molecule agonists can mitigate metastatic
melanoma progression in vivo.
DISCUSSION
We have demonstrated in the current study that in metastatic
melanoma cells, the maladaptively upregulated lysosomal ML1
channels can be pharmacologically targeted to induce a distinctive form of necrotic cell death by triggering lysosomal Zn2+
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release to cause mitochondrial swelling/damage and rapid
cellular ATP depletion (Figure 7). In contrast to ML-SA-induced
cell death that occurs rapidly (within hours) in metastatic melanoma cells, ML1 inhibition was previously reported to exhibit a
slow (in days) anti-proliferation effect in cancer cells (Jung
et al., 2019; Shekoufeh Almasi et al., 2020; Xu et al., 2019).
Whereas under physiological conditions, ML1-mediated lysosomal Zn2+ release is required for cellular homeostasis (Kukic
et al., 2013), excessive activation of this pathway in metastatic
cancer cells, such as MeWo, M12, and MDA-231-BrM2 cells,
may induce such cell death (Figure 7). Hence, lysosomal ML1
channels are maladaptively upregulated in metastatic cancer
cells, and this maladaptation, as a prognostic marker for
advanced melanoma patients, can be targeted for selective eradication of metastatic melanoma cells without affecting normal
cells.
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Figure 6. In vivo efficacy of ML-SAs on suppressing tumor growth in advanced melanoma mouse models
(A) Representative bioluminescence images (BLI) of MeWo-FmC-tumor bearing mice treated with vehicle or SA5 (5 mg/kg mouse weight).
(B) Statistical analysis of in vivo MeWo-FmC tumor growth in vehicle versus SA5-treated mice (n = 5 mice per group).
(C) Representative mCherry fluorescence imaging of MeWo-FmC tumor cells (red) in skin sections from vesicle or SA5-treated tumor bearing mice (sample
collection at day 42). Scale bar, 50 mm.
(D) The effects of drug treatment on mouse body weight.
(E) Representative bioluminescence images of M12-FmC-tumor bearing mice treated with vehicle or SA8 on day 7 after tumor implantation (before drug
administration at day 8) and day 14 (1 week after drug administration); single intracranial injection with vehicle (DMSO) or SA8 (10 mM/5 ml) was conducted at day
8.
(F) Statistical analysis of in vivo M12-FmC brain tumor growth in vehicle versus SA8-treated mice (n = 8 mice per group). Each open circle/square represents one
mouse.
(G) Kaplan-Meier survival analysis of M12-FmC tumor-bearing mice treated with vehicle or SA8 (n = 8 mice per group). Log-rank test, p < 0.001.
For all other panels, data are mean ± SEM; **p < 0.01.

Upon certain pathological challenges, such as in stroke and
neurodegenerative disorders, increases in cytoplasmic chelatable
Zn2+ reportedly cause massive neuronal cell death (Koh et al.,
1996). Unlike the cytosol, which keeps the free Zn2+ concentration
as low as 0.1 nM by multiple efflux and buffering mechanisms,
intracellular vesicles such as lysosomes contain micromolar to
millimolar concentrations of Zn2+, functioning as vesicular Zn2+
stores (Blaby-Haas and Merchant, 2014; Minckley et al., 2019;
Palmiter et al., 1996). Cancer cells, due to their high metabolism
and fast turnover of metal-binding macromolecules, tend to accumulate heavy metal ions in endolysosomal compartments (Chandler et al., 2016; Kroemer and Jäättelä, 2005; Pavlova and Thompson, 2016). Although cytosolic Zn2+, as an essential trace element,
is required for normal cellular functions, excessive Zn2+ release
from intracellular Zn2+ stores reportedly inhibits mitochondrial
functions, e.g., the electron transport chain, to cause cellular energy failure and subsequent cell death (Sheline et al., 2000).
Although our results strongly suggest lysosomal Zn2+ as the
driving force in ML-SA-caused cell death, the possible contribution of Ca2+ to the Zn2+-dominant process cannot be excluded,
as ML-SA application evokes lysosomal Ca2+ release as well (Figure S3A) (Shen et al., 2012; Yu et al., 2020).

Mitochondria have been implicated in several cell-death pathways, including apoptosis and ferroptosis (Gao et al., 2019).
During ferroptosis, mitochondria become condensed and
dysfunctional (Dixon et al., 2012). Remarkably distinct features,
such as rapid (<1 h) mitochondrial swelling and fragmentation,
occur during ML-SA-induced cell death. Although a causative
role of mitochondrial swelling/damage in such cell death requires
further investigation, the fast time course of mitochondrial swelling
suggests that it is the cause of cellular ATP depletion and cell
death. How lysosomal Zn2+ release causes mitochondrial swelling
and damage is not known. A recent study reported that Ca2+ is
transferred directly from lysosomes into mitochondria upon ML1
activation (Peng et al., 2020). It is likely that upon ML1 activation,
lysosomal Zn2+ may also rapidly flux into mitochondria through
lysosome-mitochondria membrane contact sites. We hypothesize that certain Zn2+-dependent enzymes or Zn2+ regulated mitochondrial membrane proteins may function as the key mediators
of ML-SA-induced cell death. For instance, inhibition of crucial enzymes in the ATP synthesis process, e.g., glyceraldehyde 3-phosphate dehydrogenase (GAPDH), by Zn2+ may become significant
when the free cytosolic or mitochondrial [Zn2+] is elevated (Beyersmann and Haase, 2001; Maret et al., 1999). Hence, Zn2+
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Figure 7. Activation of upregulated ML1
channels in the lysosomal Zn2+ stores induces Zn2+ release and selective necrotic
cell death in metastatic melanoma cells
Lysosome number and machinery, including
lysosomal ML1 channels, are maladaptively upregulated in metastatic melanoma cells compared
with normal melanocytes. In metastatic melanoma
cells, but not in normal melanocytes, ML-SA
administration results in excessive ML1 activation
and lysosomal Zn2+ release, causing mitochondrial swelling/damage, cellular ATP depletion, and
necrotic cell death (which we termed ‘‘Lysozincrosis’’).

release channels and transporters such as ML1 (Eichelsdoerfer
et al., 2010; Kukic et al., 2013) must be tightly regulated within
cells. ML1 upregulation might provide some growth advantage
for metastatic cancer cells. However, this upregulation may render
these ML1-upregulated cells a unique susceptibility to ML-SAs via
the lysosome-initiated, mitochondria-mediated, necrotic cell
death. Therefore, pharmacological activation of ML1 may serve
as a potential therapeutic strategy for metastatic melanoma or
other cancers, in which ML1 upregulation is a prognostic marker.
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Fisher Scientific

Cat# 31430; RRID: AB_228307

ML-SAs (SA1, SA5, SA8)

Shen et al., 2012; Sahoo et al., 2017; Yu
et al., 2020; This paper; National Institutes
of Health (NIH)/National Center for
Advancing Translational Sciences (NCATS)
Chemical Genomics Center & CalyGene
Biotechnology Inc.

N.A.

ML-SIs (SI3, SI4)

Sahoo et al., 2017; National Institutes of
Health (NIH)/National Center for Advancing
Translational Sciences (NCATS) Chemical
Genomics Center

N.A.

Chemicals, peptides, and recombinant proteins

K-Gluconate

Sigma-Aldrich

P1847; CAS: 299-27-4

NaCl

Sigma-Aldrich

S9888; CAS: 7647-14-5

EGTA

Sigma-Aldrich

E4378; CAS: 67-42-5

MgCl2

Sigma-Aldrich

208337; CAS: 7786-30-3

CaCl2

Sigma-Aldrich

C8106; CAS: 10035-04-8

MgCl2

Sigma-Aldrich

1374248; CAS: 7791-18-6

ZnCl2

Sigma-Aldrich

208086; CAS: 7646-85-7

Glucose

Sigma-Aldrich

G6152; CAS: 50-99-7

HEPES

Sigma-Aldrich

H3375; CAS: 7365-45-9

KOH

Sigma-Aldrich

P250-500; CAS: 1310-58-3

NaCl

Sigma-Aldrich

S9888; CAS: 10035-04-8

KCl

Sigma-Aldrich

P9541; CAS: 7447-40-7

MES

Sigma-Aldrich

M8250; CAS: 1266615-59-1

NaOH

Fisher Scientific

S318-500; CAS: 1310-73-2

Propidium iodide

Sigma-Aldrich

P4864

Ethanol

Decon laboratories inc.

2701; CAS: 64-17-5

Hydrogen peroxide

Sigma-Aldrich

H1009; CAS: 7722-84-1

Triton X-100

Sigma-Aldrich

T8787; CAS: 9002-93-1

NaF

Sigma-Aldrich

S7920; CAS: 7681-49-4

Na-orthovanadate

Sigma-Aldrich

S6508; CAS: 13721-39-6

Dimethyl sulfoxide (DMSO)

Sigma-Aldrich

D2650; CAS: 67-68-5

Bovine Serum Albumin (BSA)

Sigma-Aldrich

A3059; CAS: 9048-46-8

Paraformaldehyde (PFA) 4% in PBS

Fisher Scientific

J19943-K2

Phosphate-buffered saline (PBS)

Fisher Scientific

10010023

HBSS, calcium, magnesium, no phenol red

Fisher Scientific

14025092

RIPA

Boston Bioproducts

BP-115
(Continued on next page)
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Protease inhibitor cocktail

Sigma Aldrich

P8340

Phosphatase inhibitor cocktail I

Sigma Aldrich

P0044

LDS sample buffer (4x)

Invitrogen

NP0007

Pierce BCA Protein Assay

Invitrogen

23227

PVDF membrane

Millipore

IPFL00010

Tween-20

Fisher Scientific

BP337-100; CAS: 9005-64-5

SuperSignal West Atto Ultimate Sensitivity
Substrate

Fisher Scientific

A38555

LysoTrackerTM Red DND-99

Invitrogen

L7528

MitoTracker Green FM

Invitrogen

M7514

FluoZin-3, AM

Fisher Scientific

F24195

BAPTA, AM

Fisher Scientific

B6769

Tetramethylrhodamine, Methyl Ester,
Perchlorate (TMRM)

Fisher Scientific

T668

N,N,N’,N’-tetrakis(2-pyridinylmethyl)-1,2ethanediamine (TPEN)

Cayman Chemical

13340; CAS: 16858-02-9

Deferoxamine (Radford and Lippard)

Cayman Chemical

14595; CAS: 138-14-7

Chloroquine

Cayman Chemical

30708; CAS: 50-63-5

z-VAD-FMK

Cayman Chemical

14467; CAS: 161401-82-7

Bafilomycin-A1

Cayman Chemical

11038; CAS: 88899-55-2

Doxycycline

Sigma-Aldrich

D9891; CAS: 24390-14-5

1,10-Phenanthroline (hydrate)

Cayman Chemical

28951; CAS: 5144-89-8

Necrostatin-1

Cayman Chemical

11658; CAS: 4311-88-0

EGTA, AM

Cayman Chemical

20401; CAS: 99590-86-0

Doxorubicin

Cayman Chemical

15007; CAS: 25316-40-9

Zinc Pyrithione

Cayman Chemical

29154; CAS: 13463-41-7

Lipofectamine 2000

Invitrogen

11668-027

DMEM medium without phenol red

GIBCO

21063029

DMEM, high glucose

GIBCO

11965092

DMEM/F-12

GIBCO

11320033

Ham’s F-10 Nutrient Mix

Fisher Scientific

11550043

Minimum Essential Media

Fisher Scientific

11095080

Trypsin-EDTA (0.05%), phenol red

GIBCO

25300054

Fetal bovine serum (FBS)

Gemini Bio-Products

100-106

Antibiotic-Antimycotic

GIBCO

15240062

Poly-D-lysine solution

Millipore

A-003-E

Poly-L-lysine hydrobromide

Sigma-Aldrich

P1399; CAS: 25988-63-0

Vacuolin-1

Sigma-Aldrich

673000; CAS: 351986-85-1

Ionomycin

Sigma-Aldrich

I9657; CAS: 56092-81-0

Tissue-Tek O.C.T. (Optimal Cutting
Temperature) compound

Sakura Finetek

4583

Polyethylene glycol (PEG) 300

Sigma-Aldrich

1546423; CAS: 25322-68-3

XenoLight D-Luciferin - K+ Salt
Bioluminescent Substrate

PerkinElmer

122799

CellTiter-Glo Luminescent Cell Viability
Assay

Promega

G7571

E.Z.N.A. Total RNA Kit I

Omega Bio-tek

R6834-01

Critical commercial assays

(Continued on next page)
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SuperScript III One-Step RT-PCR System

Fisher Scientific

12574026

PowerUp SYBR Green Master Mix

Fisher Scientific

A25741

Q5 High-Fidelity DNA Polymerase

New England Biolabs

M0491S

GoTaqTM master mixes

Promega

M7122

MycoAlertTM Mycoplasma Detection Kit

Lonza

LT07-318

pMEL/NRAS (Q61R) immortalized human
melanocyte

A gift from Dr. D. Fisher, MGH

N.A.

Human MeWo cells

ATCC

HTB-65

Human M12 cells

A gift from Dr. J. Sarkaria, Mayo Clinic; Du
et al., 2017

N.A.

Human MDA231BrM2a cells

A gift from Dr. J. Massague, Memorial Sloan
Cancer Center Bos et al., 2009

N.A.

Human skin fibroblast cells

Obtained from the Coriell Institute for
Medical Research

clone GM05659

Experimental models: Cell lines

Human: HEK293 cells

ATCC

CRL- 1573

Human: HeLa cells

ATCC

CCL-2

Human SH-SY5Y cells

ATCC

CRL-2266

TFEB-GFP Stable HeLa cells

Zhang et al., 2016; Zhang et al., 2019

N.A.

Human HEK293-GCaMP7-ML1 cells

Zhang et al., 2019

N.A.

Human M12-FmC cells

Du et al., 2017

N.A.

Human MeWo-FmC cells

Du et al., 2017

N.A.

Human paraffin-embedded tissue array
(Tissue Microarray, TMA)

US Biomax

ME1004

Athymic Nude Mouse

Charles River Laboratories

490 Crl:NU(NCr)-Foxn1nu

Experimental models: Organisms/strains

Oligonucleotides
GAPDH, forward primer

50 -tgcaccaccaactgcttagc-30
0

N.A.
0

GAPDH, reverse primer

5 -ggcatggactgtggtcatgag-3

MCOLN1, forward primer

50 -gagtgggtgcgacaagtttc-30

N.A.

MCOLN1, reverse primer

50 -tgttctcttcccggaatgtc-30

N.A.

Stealth siRNA human TFEB

Fisher Scientific

HSS111868

MISSION esiRNA targeting human
MCOLN1

Sigma-Aldrich

EHU062561

GZnP3-ML1

A gift from Dr. Yan Qin, Denver University;
Minckley et al., 2019

N.A.

GZnP3-Rab7

A gift from Dr. Yan Qin, Denver University;
Minckley et al., 2019

N.A.

N.A.

Recombinant DNA

EGFP-ML1

Shen et al., 2012

N.A.

ML1-L15L/AA-L577L/AA (abbreviated as
ML1-4A)

Shen et al., 2012

N.A.

MetaMorph 7.10

Molecular Devices

https://www.moleculardevices.com/

pClamp 10.7

Molecular Devices

https://www.moleculardevices.com/

OriginPro 2018

Originlab

https://www.originlab.com/

GraphPad Prism 8

Graphpad

https://www.graphpad.com/

Fiji/ImageJ

Fiji contributors

https://imagej.net/software/fiji

Software and algorithms
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RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Wanlu Du
(wanludu@umich.edu).
Materials availability
All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer
Agreement.
Data and code availability
d
d
d

All data reported in this paper will be shared by the lead contact upon request.
This paper does not report original code.
Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal models
Athymic nude mice (females, 8 weeks old, Charles River Laboratories, Wilmington, MA) were used in this study. Mice were housed in
standard cages at 21 C with a 12h light-12h dark cycle with access to food (standard laboratory chow) and water ad libitum. Based
on pilot studies, with a power of 0.8 and p < 0.05, we calculated a sample size of between 5 and 11 mice per group. Mice were anesthetized using 2% isoflurane (inhale). For the subcutaneous (s.c.) tumor model, MeWo-FmC cells (11.5x106 tumor cells/mouse)
were suspended in 100 mL PBS and s.c. injected into immunocompromised nude mice. ML-SA5 (dissolved in 10% DMSO, 40%
PEG300, and 50% PBS) (Yu et al., 2020) was administered to mice (5 mg/Kg) by intraperitoneal (i.p) injection 3 times a week until
the end of experiments. Mice with one of the following conditions: 1) a tumor diameter measuring greater than 2 cm in any single
dimension, 2) impairment in the normal movement, 3) ulceration that is greater than 1/2 the surface of the tumor area or has effusions,
4) infection, and 5) hemorrhage, were euthanized according to the Tumor Burden Policy for Rodents. For the MBM tumor model,
M12-FmC cells were implanted stereotactically into nude mouse brains (0.5 3 105 tumor cells/mouse) in the following co-ordinates:
2.2 mm lateral from bregma, 2.5 mm ventral from dura on the cranial suture. ML-SA8 (10 mM/5 ml) was administered on-site by a
single intracranial injection. Mice were imaged for the success of tumor cell injection post-implantation and then periodically for tumor progression using in vivo bioluminescent imaging as described previously (Du et al., 2017). During tumor growth, we closely
monitored the animal situation and strictly followed the Tumor Burden Policy for Rodents and the End-Stage Illness Scoring System
for euthanizing the mice that reached a score of 6-11. All in vivo procedures were approved by animal protocol following the Institutional Animal Care Guidelines at the University of Michigan.
Cell culture
The pMEL/NRAS (Q61R) immortalized human melanocytes were cultured in Ham’s F-10 Nutrient Mix with 10% fetal bovine serum
(FBS) and 1% penicillin-streptomycin. The patient-derived melanoma brain metastatic cells, M12 and MeWo, as well as HEK293,
MDA231BrM2, HeLa, and SH-SY5Y cell lines, were cultured in Dulbecco’s Modified Eagle Medium supplemented with 10% FBS
and 1% penicillin-streptomycin. Human fibroblasts were cultured in Minimum Essential Media supplemented with 10% FBS and
1% penicillin-streptomycin. All cells were used at low passages with occasional testing for mycoplasma contamination by
MycoAlertTM Mycoplasma Detection Kit.
METHOD DETAILS
Whole-endolysosome and whole-cell patch-clamp electrophysiology
Whole-endolysosome patch-clamp experiments were performed in isolated enlarged endolysosomes as described previously (Dong
et al., 2008; Zhang et al., 2019). Briefly, cells were treated with 1 mM vacuolin-1 overnight to selectively enlarge the size of late endosomes and lysosomes (LELs). A glass electrode was then used to break the plasma membrane to release the enlarged vacuoles. After
formation of a giga-seal between the patch pipette and an enlarged endolysosome, voltage steps of several hundred millivolts with a
millisecond duration were applied to break into the vacuolar membrane. All bath solutions were applied via a fast perfusion system
that produced a complete solution exchange within a few seconds. Unless otherwise indicated, the bath (cytoplasmic) solution contained (in mM): 140 K-gluconate, 4 NaCl, 1 EGTA, 2 MgCl2, 0.39 CaCl2, and 20 HEPES (pH 7.2 adjusted with KOH; free [Ca2+]i approximately equal to 100 nM). The pipette (luminal) solution contained (in mM): 145 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 glucose, 10 HEPES,
and 10 MES (pH 4.6 adjusted with NaOH). For whole-cell patch clamp recordings, the pipette (cytosolic) solution contained (in mM):
145 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 glucose, and 10 HEPES (pH 7.4 adjusted with NaOH). The bath (extracellular) solution
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contained (in mM): 30 ZnCl2, 110 NaCl, 10 HEPES, and 10 MES (pH 4.6 adjusted with HCl). Glass electrodes were pulled with resistance of 2–4 mU (whole-cell) or 9-11 mU (whole-endolysosome). Data were collected using an Axopatch 200B amplifier equipped
with a Digidata 1440 controlled by Clampex 10.7 software. All experiments were conducted at room temperature (22 C–25 C),
and all recordings were analyzed with Clampfit 10.7 and Origin 2018 software.
RNA extraction and RT-qPCR
Total RNA was extracted from the cultured cells using E.Z.N.A. total RNA kit. The cDNA was then synthesized using a Superscript III RT
kit. PCR mixture was prepared with Power-Up SYBR green 2X master mix using the following primers: GAPDH, forward (fw): 50 -tgcac
caccaactgcttagc-30 , reverse: 50 -ggcatggactgtggtcatgag-30 ; MCOLN1, fw: 50 -gagtgggtgcgacaagtttc-30 , rev: 50 -tgttctcttcccggaatgtc-30 .
Real time quantitative PCR was performed with the ABI StepOnePlus RealTime PCR System.
Western blotting
Cells were lysed with ice-cold RIPA buffer in the presence of 1X protease inhibitor cocktail and phosphatase inhibitor cocktail 2, NaF
(1 mM), and Na3VO4 (1 mM). Protein samples (10– 100 mg) were then loaded and separated on 4% to 12% gradient sodium dodecyl
sulfate (SDS) polyacrylamide electrophoresis gels and transferred to polyvinylidene difluoride membranes. The membranes were
blocked with 1% bovine serum albumin (BSA) or 5% milk in PBS supplemented with 0.1% Tween20 for 1 h and then incubated
with primary antibodies against ML1, LAMP1, and b-actin. Bound antibodies were detected with horseradish peroxidase-conjugated
anti-rabbit or anti-mouse secondary antibodies and enhanced chemiluminescence reagents. Protein levels were quantified using the
ImageJ (NIH) software.
Immunohistochemistry (IHC)
Human paraffin-embedded tissue array (Tissue Microarray, TMA) contained multiple benign tumor (nevus) and metastatic melanoma
specimens. Immunohistochemical staining was performed at the University of Michigan Rogel Cancer Center Histology core on the
DAKO Autostainer (Agilent, Carpinteria, CA) using Envision Flex+ and diaminobenzadine (DAB) as the chromogen. De-paraffinized
sections were labeled with anti-TRPML1 specific antibody at 1:250 for 30 mins at room temperature. Heat induced epitope retrieval
using Dako Envision Flex TRS, Low pH was used prior to staining. Appropriate negative (no primary antibody) and positive controls
(Titer TMA 4A) were stained in parallel with each set of slides studied. Images were obtained by Nikon’s Eclipse E800 microscope.
In vitro cell death assay
Cell death was analyzed by either propidium iodide (PI) staining or CellTiter-Glo Luminescent Cell Viability Assay. For PI staining,
cells were washed twice with cold PBS before being incubated with 10 mg/mL PI for 10 min. Images were acquired with Canon fluorescence microscope and analyzed using ImageJ. For CellTiter-Glo luminescent cell viability assay, cells (0.51 3 104/well) were
seeded in 96-well plates and incubated with various chemicals for indicated time periods. Cell viability was measured by a quantitative luminescence assays using an ATP-dependent luminescent reagent according to the manufacturer’s instruction manual.
Silencing RNA knockdown
ML1 and TFEB siRNA knockdown were achieved with esiRNA human MCOLN1 (esiRNA1) or stealth siRNA human TFEB transfections by Lipofectamine 2000. The efficiency of the siRNA knockdown was assayed by western blotting or qPCR. Cells were then
subjected to electrophysiological and cell biological analyses 72 hours after transfection.
Expression of ML1 in HEK293 cells
GCaMP7-ML1 expression was induced in Tet-On HEK293-GCaMP7-ML1 cells (Zhang et al., 2019) 24h prior to experiments by adding 0.01 mg/mL doxycycline (Dox). For HEK ML1 OE cells, transient transfection of EGFP-ML1 was performed in HEK293 cells using
Lipofectamine 2000.
FluoZin-3, LysoTracker, and MitoTracker Imaging
Fluorescence and time-lapse imaging was conducted in a spinning-disk confocal imaging system composed of an Olympus IX81 inverted microscope, 10 3 , 20 3 , and 60 3 Olympus objectives, a CSU-X1 scanner (Yokogawa), an iXon EM-CCD camera (Andor), a
temperature controller, and MetaMorph Advanced Imaging acquisition software v.7.7.8.0. FluoZin-3-AM and LysoTracker were loaded
according to the manufacturer’s instructions. Briefly, FluoZin-3AM (1 mM stock solution in DMSO) was diluted to a final concentration of
3 mM in respective culture mediums. A 1 mM stock solution of LysoTracker RED DND-99 was diluted to a final concentration of 0.5 mM in
respective culture mediums. Cells were loaded with the dye-containing buffer for 30 min before image collection. For time-lapse imaging
of PI fluorescence (Videos S1 and S2), cells were challenged with DMEM supplemented with 10 mg/mL PI, and images were taken at an
interval of 5 or 10 min for M12 cells and MeWo cells, respectively. For MitoTracker live imaging, cells were loaded with MitoTracker and
treated with ML-SAs (1h for melanocytes and MeWo cells, 30 min for M12 cells). For most inhibitor experiments, drugs were pretreated
for 30 min. Images were acquired and analyzed with MetaMorph Advanced imaging acquisition software v.7.7.8.0 and ImageJ (NIH).
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Electron microscopy
EM was performed at the Microscopy Core at the University of Michigan. Briefly, M12 cells were plated in the conventional TEM cell
monolayer consumables (4 Thermanox 8mm coverslips and a 12-well culture plate). Cells were treated with DMSO or SA5 (3 mM) for
30 min, fixed with 2.5% glutaraldehyde in 0.1M sodium cacodylate buffer, and then processed for Epon embedding (Electron
Microscopy Sciences, 14,120). Sections of 70 nm were mounted onto Formvar-coated nickel grids (Electron Microscopy Sciences,
FF200-Ni) and double contrasted with 2% uranyl acetate (Electron Microscopy Sciences, 22400) for 5 min and 3% lead citrate
(Electron Microscopy Sciences, 17810) for 5 min. Grids were imaged using a JEM 1400plus TEM imaging system with an AMT
XR81M-B camera. Mitochondria were morphologically identified. Images were analyzed using ImageJ.
GZnP3 Zn2+ imaging
GZnP3 imaging was performed in HEK293 and MeWo cells that were transiently transfected with GZnP3-ML1 or GZnP3-Rab7 as
described previously (Minckley et al., 2019). The fluorescence intensity at 488 nm was recorded with an EasyRatioPro system
(Photon Technology International, Inc. New Jersey, USA).
QUANTIFICATION AND STATISTICAL ANALYSIS
Average data are presented as means ± standard errors of the mean (SEMs). Statistical comparisons were made by using Student’s t
test or one way ANOVA. Differences were considered significant at *p < 0.05, ** p < 0.01, *** p < 0.001. Survival curves were compared
using the Log-rank test. All data analyses were conducted using Origin Pro 2019 or GraphPad Prism 8.0.
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Figure S1. Lysosomal ML1 channels are upregulated in metastatic melanoma cells. Related to Figure 1.
(A) RT-qPCR analysis of ML1 mRNA expression in normal melanocytes, MeWo, and M12 cells. Each open circle
represents the average result from one batch of cells. (B) Western blotting analysis of ML1 and LAMP1 protein
expression. β-actin served as the loading control. (C, D) Normalized ML1 and LAMP1 protein expression levels in normal
melanocytes, MeWo, and M12 cells. (E) ML-SA1 (SA1), ML-SA5 (SA5), and ML-SA8 (SA8) dose-dependently activated
IML1. (F) IML1 was activated and inhibited by ML-SA and ML-SI compounds, respectively, in a cytoplasmic-side-out
endolysosomal patch from a MeWo cell. (G) LysoTracker staining of normal melanocytes, MeWo, and M12 cells. Scale
bar = 10 μm. Right panels show the relative fluorescence intensity of LysoTracker in melanocytes (n=19 randomly selected
cells), MeWo cells (n=31), and M12 cells (n=24). Average data are presented as the mean ± SEM; cells are randomly
selected for analysis from at least three independent experiments; ** p < 0.01, *** p < 0.001.
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Figure S2. Small-molecule activation of lysosomal ML1 channels induces cell death in metastatic melanoma cells.
Related to Figure 2.
(A) Cell viability analyses of MeWo and M12 cells treated with ML-SI3 (0~100 μM) or ML-SI4 (0~100 μM) for 12 hrs.
(B) Overlay phase contrast (Ph) and fluorescence images of PI-stained indicated cells in the presence of SA5 (3 μM) or
SA8 (1 μM) for indicated time periods. Scale bar, 25 μm. Time-dependent effects of SA5/8 on PI-positive cell percentages
are also shown in the right panels. (C) Effects of SI4 (20 μM, 12h) on SA5-induced cytotoxicity in M12 cells. (D) The
effects of SA5 and SA8 on the percentages of PI-positive HEK293 cells. (E, F) The effects of ML-SIs on SA8-induced
cell death in ML1-overexpressing HEK293 cells. All data are presented as the mean ± SEM; * p < 0.05; *** p < 0.001.
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Figure S3. Ca2+ and TFEB are not required for ML-SA-induced cytotoxicity in metastatic melanoma cells. Related
to Figure 3.
(A)The effects of BAPTA-AM (20 μM) and TPEN (10 μM) pre-treatment on SA5-evoked lysosomal Ca2+ release,
measured by GCaMP7 Ca2+ imaging (F470) in HEK293-GCaMP7-ML1 cells. SA5 (3 µM) was bath applied in a low or
'zero' Ca2+ (free [Ca2+] < 10 nM) external solution. BAPTA-AM and TPEN were added to the cells 30 min prior to SA5
treatment. Ionomycin served as a positive control to induce the maximal Ca2+ response. (B) The effects of BAPTA-AM
(20 μM) or TPEN (10 μM) treatment on SA5 (1 μM/30 min)-induced TFEB nuclear translocation in HeLa cells stably
expressing TFEB-GFP. Scale bar, 10 μm. (C) Cell viability analysis of M12 cells that were treated with SA5 for 12h in
the presence or absence of EGTA-AM (20 μM) or TPEN (2.5 μM). (D) Cell viability analysis of M12 cells that were
treated with SA5 for 12h in the presence of Cyclosporin A (CsA, 10 μM) or TPEN (2.5 μM). (E) Cell viability analysis of
control, scramble or siTFEB-transfected M12 cells that were treated with various concentration of SA5 for 24h. Left panels
show the knockdown effect of siTFEB on TFEB protein expression.
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Figure S4. Zn2+ chelation prevents ML-SA-induced cytotoxicity in metastatic melanoma cells. Related to Figure 4.
(A) Representative images of FluoZin-3 staining in M12 cells that were incubated with Zinc Pyrithione (PYZ, 3 μM/1hr),
PYZ+TPEN (10 μM), and PYZ+1,10-PT (50 μM). Right panels show the statistical analyses of relative FluoZin-3
intensities of M12 cells that were treated with PYZ (n=49 cells), PYZ+TPEN (n=50 cells), or PYZ+1,10-PT-treated (n=15
cells). (B) PI staining of MeWo and M12 cells that were pretreated with BAPTA-AM (10 μM) or TPEN (2.5 μM) in the
presence of SA8 (1 μM) treatment. (C) The percentage of PI-positive cells as shown in (B). Each open circle represents
one batch of cells. Note that the control groups of MeWo and M12 cells treated with ML-SA8 are re-plotted from Figure
2J, as they were from the same experiments. (D) Cell viability analysis of SA5-treated M12 cells in the presence or
absence of 1,10-PT (10 μM). (E) PI staining of ML1-overexpressing HEK293 cells (HEK293 ML1 OE) upon SA8
treatment (1 μM) for 6h in the presence or absence of BAPTA-AM (10 μM) or TPEN (2.5 μM). Note that left two panels
are controls replotted from Figure S2E, as they were from the same experiments. (F) The percentages of PI-positive
HEK293 cells as shown in (E). (G) Whole-cell ML1 currents in ML1-4A-transfected HEK293 cells in the presence of
Tyrode’s or high Zn2+ solutions. (H) FluoZin-3 and LysoTracker staining of M12 cells treated with Baf-A1 (0.5 μM, 1h).
Right panels show the relative fluorescence intensity of FluoZin-3 or LysoTracker. Scale bar = 5 μm. Each open circle
represents one individual cell. All data are presented as the mean ± SEM; * p < 0.05; ** p < 0.01; *** p < 0.001.
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Figure S5. Lack of effects of known cell death inhibitors on ML-SA5-induced cytotoxicity. Related to Figure 5.
(A) Cell viability analysis of M12 cells that were treated with various concentration of SA5 for 12h in the presence or
absence of necrostatin-1 (Nec-1, 20 μM). (B) Cell viability analysis of M12 cells that were treated with SA5 (3 μM; 12h)
in the presence or absence of pan-caspase inhibitor z-VAD-fmk (20 μM). Doxorubicin (DOX, 3 μM; 12h) was used to
show the positive control effect of z-VAD-fmk. (C) Cell viability analysis of MeWo cells that were treated with various
concentration of SA5 for 12h in the presence or absence of DFO (200 μM). Right panels show the positive-control effects
of DFO on cell viability of HeLa cells treated with Erastin (30 μM, 24h). (D) Cell viability analysis of MeWo cells that
were treated with SA5 (3 μM, 12h) in the presence or absence of chloroquine (CQ, 20 μM). (E) Cell viability analysis of
M12 cells that were treated with various concentration of SA5 for 12h in the presence or absence of Baf-A1 (0.5 μM). All
data are presented as the mean ± SEM; *** p < 0.001.
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Figure S6. ML-SA5 treatment causes a loss of mitochondrial membrane potential in metastatic melanoma cells.
Related to Figure 5.
Representative images of DIC and TMRM staining of M12 cells treated with DMSO (control) or SA5 (3 μM/0.5h). Scale
bar = 10 μm. Right panel, TMRM staining shows reduced mean pixel intensity after SA5 treatment. All data are presented
as the mean ± SEM; *** p < 0.001.

Survival Percentage (%)

120
100
80
60

Vehicle

40

SA5

20
0

0

10

20

30

40

50

60

70

80

Days after tumor implantation

90

Figure S7. Survival analysis of mice bearing MeWo-FmC subcutaneous tumors. Related to Figure 6.
Nude mice were s.c. injected with 1.5x106 MeWo-FmC cells. One week later, tumor-bearing mice were randomly assigned
to vehicle (n=6 mice) vs. SA5 treated group (n=7). Vehicle or ML-SA5 was administrated to mice through i.p. injection
3 times every week until the end of experiment. Survival curves were compared using the Log-rank test, p < 0.01.

